What is claimed is:
1. An isolated polynucleotide comprising a nucleotide sequence that has at least 80% identity over its entire length to a nucleotide sequence encoding the ASP2 polypeptide of SEQ ID NO:2; or a nucleotide sequence complementary to said isolated polynucleotide.
2. The polynucleotide of claim 1 wherein said polynucleotide comprises the nucleotide sequence contained in SEQ ID NO:1 encoding the ASP2 polypeptide of SEQ ID NO02.
3. The polynucleotide of claim 1 wherein said polynucleotide comprises a nucleotide sequence that is at least 80% identical to that of SEQ ID NO:1 over its entire length.
4. The polynucleotide of claim 3 which is polynucleotide of SEQ ID NO: 1.
5. The polynucleotide of claim 1 which is DNA or RNA.
6. A DNA or RNA molecule comprising an expression system, wherein said expression system is capable of producing a ASP2 polypeptide comprising an amino acid sequence, which has at least 80% identity with the polypeptide of SEQ ID NO:2 when said expression system is present in a compatible host cell.
7. A host cell comprising the expression system of claim 6.
8. A process for producing a ASP2 polypeptide comprising culturing a host of claim 7 under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture.
9. A process for producing a cell which produces a ASP2 polypeptide thereof comprising transforming or transfecting a host cell with the expression system of claim 6 such that the host cell, under appropriate culture conditions, produces a ASP2 polypeptide.
10. A ASP2 polypeptide comprising an amino acid sequence which is at least 80% identical to the amino acid sequence of SEQ ID NO:2 over its entire length.
11. The polypeptide of claim 10 which comprises the amino acid sequence of SEQ ID NO:2.
12. An antibody immunospecific for the ASP2 polypeptide of claim 10.
13. A method for the treatment of a subject in need of enhanced activity or expression of ASP2 polypeptide of claim 10 comprising:
(a) administering to the subject a therapeutically effective amount of an agonist to said polypeptide; andor
(b) providing to the subject an isolated polynucleotide comprising a nucleotide sequence that has at least 80% identity to a nucleotide sequence encoding the ASP2 polypeptide of SEQ ID NO:2 over its entire length; or a nucleotide sequence complementary to said nucleotide sequence in a form so as to effect production of said polypeptide activity in vivo.
14. A method for the treatment of a subject having need to inhibit activity or expression of ASP2 polypeptide of claim 10 comprising:
(a) administering to the subject a therapeutically effective amount of an antagonist to said polypeptide; andor
(b) administering to the subject a nucleic acid molecule that inhibits the expression of the nucleotide sequence encoding said polypeptide; andor
(c) administering to the subject a therapeutically effective amount of a polypeptide that competes with said polypeptide for its ligand, substrate, or receptor.
15. A process for diagnosing a disease or a susceptibility to a disease in a subject related to expression or activity of ASP2 polypeptide of claim 10 in a subject comprising:
(a) determining the presence or absence of a mutation in the nucleotide sequence encoding said ASP2 polypeptide in the genome of said subject; andor
(b) analyzing for the presence or amount of the ASP2 polypeptide expression in a sample derived from said subject.
16. A method for identifying compounds which inhibit (antagonize) or agonize the ASP2 polypeptide of claim 10 which comprises:
(a) contacting a candidate compound with cells which express the ASP2 polypeptide (or cell membrane expressing ASP2 polypeptide) or respond to ASP2 polypeptide; and
(b) observing the binding, or stimulation or inhibition of a functional response; or comparing the ability of the cells (or cell membrane) which were contacted with the candidate compounds with the same cells which were not contacted for ASP2 polypeptide activity.
17. An agonist identified by the method of claim 16.
18. An antagonist identified by the method of claim 16.
19. A recombinant host cell produced by a method of claim 9 or a membrane thereof expressing a ASP2 polypeptide.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. An intraocular lens configured for implantation in a capsular sac following extraction of a natural lens, the intraocular lens accommodating in response to movement of the capsular sac, the intraocular lens comprising:
an optic portion including a lens element, an intermediate layer and an actuator, the actuator disposed in contact with the lens element;
a haptic having an interior volume coupled in fluid communication with the actuator;
a fluid disposed in the actuator and the interior volume of the haptic; and
a secondary deflection mechanism coupled to the lens element,
wherein the lens element is configured to be deformed by movement of the actuator in response to movement of the first fluid between the haptic and the actuator, and
wherein the secondary deflection mechanism is configured to further deform the lens element in response to deformation of the lens element by the actuator.
2. The intraocular lens of claim 1 wherein the secondary deflection mechanism is a portion of the lens element having a reduced thickness.
3. The intraocular lens of claim 1 wherein the secondary deflection mechanism is a flexible coupling between the lens element and the intermediate layer.
4. The intraocular lens of claim 1 wherein the secondary deflection mechanism is a fluid-mediated actuator comprising a sealed cavity between the lens element and the intermediate later that is filled with a second fluid, and
wherein deformation of the lens element and movement of the actuator redistributes the second fluid within the sealed cavity which further deforms the lens element.
5. The intraocular lens of claim 4 wherein the first fluid and the second fluid have approximately the same refractive index.
6. The intraocular lens of claim 4 wherein the lens element and the actuator are configured such that the volume of a peripheral portion of the sealed cavity decreases and the volume of a central portion of the sealed cavity increases when the first fluid is transferred from the haptic to the actuator.
7. The intraocular lens of claim 1 further comprising a backstop coupled to at least a portion of the haptic.
8. The intraocular lens of claim 1 further comprising a support member that extends further radially outward than the haptic.
9. The intraocular lens of claim 1 wherein the actuator includes a rolling undulation.
10. The intraocular lens of claim 1 wherein the actuator includes a bellows.
11. The intraocular lens of claim 1 wherein the intermediate layer and the actuator are monolithic.
12. The intraocular lens of claim 1 wherein the intermediate layer and the actuator are separate components coupled together.
13. The intraocular lens of claim 4 wherein the lens element and the intermediate layer are sealed such that relative motion adjacent the seal is permitted.
14. The intraocular lens of claim 1 wherein the lens element is deformed to an aspheric configuration by the actuator and secondary deflection mechanism.
15. An intraocular lens configured for implantation in a capsule following extraction of a natural lens, the intraocular lens accommodating in response to shape changes of the patient’s lens capsule, the intraocular lens comprising:
an optic portion including a lens element, an actuator and a sealed fluid cavity adjacent at least a portion of the lens element;
a haptic having an interior volume coupled in fluid communication with the actuator, and a capsule wall contacting portion;
a first fluid disposed in the actuator and the interior volume of the haptic; and
a second fluid disposed in the sealed fluid cavity,
wherein the actuator is coupled with the lens element such that shape changes of the patient’s lens capsule displaces fluid between the interior volume of the haptic and the actuator to change a deflection of the lens element, and
wherein deflection of the lens element causes the second fluid to redistribute within the sealed fluid cavity to alter the deflection of the lens element.
16. The intraocular lens of claim 15 further comprising a backstop coupled to at least a portion of the haptic.
17. The intraocular lens of claim 15 further comprising a support member that extends further radially outward than the haptic.
18. The intraocular lens of claim 17 wherein the support member is a wire that circumscribes and is radially spaced from the haptic.
19. The intraocular lens of claim 17 wherein the support member is a tab that extends radially outward from a portion of the haptic.
20. The intraocular lens of claim 15 wherein the support member is integrated into the haptic.